Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen
Läs mer

Forskning på covid-vacciner fortsätter öka

Forskningen på vacciner mot covid-19 fortsätter att öka i omfattning. Nu finns 236 vaccinkandidater under utveckling globalt, varav 63 har börjat testas i kliniska prövningar.

– Det är viktigt med omfattande forskning på vacciner mot covid-19. Det kommer att krävas ett antal vacciner för att möta det stora globala behovet, säger Jonas Vikman, Lifs samhällspolitiske chef och vaccinexpert.
Läs mer

Imfinzi approved in the EU for less-frequent, fixed- dose use in unresectable non-small cell lung cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Läs mer